Analysis of urinary oligosaccharide excretion patterns by UHPLC/HRAM mass spectrometry for screening of lysosomal storage disorders

Author:

Hagemeijer Marne C.1,van den Bosch Jeroen C.1,Bongaerts Michiel1,Jacobs Edwin H.1,van den Hout Johanna M. P.2,Oussoren Esmee2,Ruijter George J. G.1

Affiliation:

1. Center for Lysosomal and Metabolic Diseases, Department of Clinical Genetics Erasmus University Medical Center Rotterdam The Netherlands

2. Center for Lysosomal and Metabolic Diseases, Department of Pediatrics Erasmus University Medical Center Rotterdam The Netherlands

Abstract

AbstractOligosaccharidoses, sphingolipidoses and mucolipidoses are lysosomal storage disorders (LSDs) in which defective breakdown of glycan‐side chains of glycosylated proteins and glycolipids leads to the accumulation of incompletely degraded oligosaccharides within lysosomes. In metabolic laboratories, these disorders are commonly diagnosed by thin‐layer chromatography (TLC) but more recently also mass spectrometry‐based approaches have been published. To expand the possibilities to screen for these diseases, we developed an ultra‐high‐performance liquid chromatography (UHPLC) with a high‐resolution accurate mass (HRAM) mass spectrometry (MS) screening platform, together with an open‐source iterative bioinformatics pipeline. This pipeline generates comprehensive biomarker profiles and allows for extensive quality control (QC) monitoring. Using this platform, we were able to identify α‐mannosidosis, β‐mannosidosis, α‐N‐acetylgalactosaminidase deficiency, sialidosis, galactosialidosis, fucosidosis, aspartylglucosaminuria, GM1 gangliosidosis, GM2 gangliosidosis (M. Sandhoff) and mucolipidosis II/III in patient samples. Aberrant urinary oligosaccharide excretions were also detected for other disorders, including NGLY1 congenital disorder of deglycosylation, sialic acid storage disease, MPS type IV B and GSD II (Pompe disease). For the latter disorder, we identified heptahexose (Hex7), as a potential urinary biomarker, in addition to glucose tetrasaccharide (Glc4), for the diagnosis and monitoring of young onset cases of Pompe disease. Occasionally, so‐called “neonate” biomarker profiles were observed in young patients, which were probably due to nutrition. Our UHPLC/HRAM‐MS screening platform can easily be adopted in biochemical laboratories and allows for simple and robust screening and straightforward interpretation of the screening results to detect disorders in which aberrant oligosaccharides accumulate.

Publisher

Wiley

Subject

Genetics (clinical),Genetics

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3